dc.contributor.author |
Metcalf, Tatiana |
|
dc.contributor.author |
Soria, Jaime |
|
dc.contributor.author |
Montano, Silvia M. |
|
dc.contributor.author |
Ticona, Eduardo |
|
dc.contributor.author |
Evans, Carlton Anthony William |
|
dc.contributor.author |
Huaroto, Luz |
|
dc.contributor.author |
Kasper, Matthew |
|
dc.contributor.author |
Ramos, Eric S. |
|
dc.contributor.author |
Mori, Nicanor |
|
dc.contributor.author |
Jittamala, Podjanee |
|
dc.contributor.author |
Chotivanich, Kesinee |
|
dc.contributor.author |
Chavez, Irwin F. |
|
dc.contributor.author |
Singhasivanon, Pratap |
|
dc.contributor.author |
Pukrittayakamee, Sasithon |
|
dc.contributor.author |
Zunt, Joseph R. |
|
dc.date.accessioned |
2018-11-30T03:10:46Z |
|
dc.date.available |
2018-11-30T03:10:46Z |
|
dc.date.issued |
2018 |
|
dc.identifier.uri |
https://hdl.handle.net/20.500.12866/4065 |
|
dc.description.abstract |
BACKGROUND: Meningitis caused by Mycobacterium tuberculosis is a major cause of morbidity and mortality worldwide. We evaluated the performance of cerebrospinal fluid (CSF) testing with the GeneXpert MTB/RIF assay versus traditional approaches for diagnosing tuberculosis meningitis (TBM). METHODS: Patients were adults (n = 37) presenting with suspected TBM to the Hospital Nacional Dos de Mayo, Lima, Peru, during 12 months until 1st January 2015. Each participant had a single CSF specimen that was divided into aliquots that were concurrently tested for M. tuberculosis using GeneXpert, Ziehl-Neelsen smear and culture on solid and liquid media. Drug susceptibility testing used Mycobacteria Growth Indicator Tube (MGIT 960) and the proportions method. RESULTS: 81% (30/37) of patients received a final clinical diagnosis of TBM, of whom 63% (19/30, 95% confidence intervals, CI: 44-80%) were HIV-positive. 22% (8/37, 95%CI: 9.8-38%), of patients had definite TBM. Because definite TBM was defined by positivity in any laboratory test, all laboratory tests had 100% specificity. Considering the 30 patients who had a clinical diagnosis of TBM: diagnostic sensitivity was 23% (7/30, 95%CI: 9.9-42%) for GeneXpert and was the same for all culture results combined; considerably greater than 7% (2/30, 95%CI: 0.82-22%) for microscopy; whereas all laboratory tests had poor negative predictive values (20-23%). Considering only the 8 patients with definite TBM: diagnostic sensitivity was 88% (7/8, 95%CI: 47-100%) for GeneXpert; 75% (6/8, 95%CI: 35-97%) for MGIT culture or LJ culture; 50% (4/8, 95%CI 16-84) for Ogawa culture and 25% (2/8, 95%CI: 3.2-65%) for microscopy. GeneXpert and microscopy provided same-day results, whereas culture took 20-56 days. GeneXpert provided same-day rifampicin-susceptibility results, whereas culture-based testing took 32-71 days. 38% (3/8, 95%CI: 8.5-76%) of patients with definite TBM with data had evidence of drug-resistant TB, but 73% (22/30) of all clinically diagnosed TBM (definite, probable, and possible TBM) had no drug-susceptibility results available. CONCLUSIONS: Compared with traditional culture-based methods of CSF testing, GeneXpert had similar yield and faster results for both the detection of M. tuberculosis and drug-susceptibility testing. Including use of the GeneXpert has the capacity to improve the diagnosis of TBM cases. |
en_US |
dc.language.iso |
eng |
|
dc.publisher |
Public Library of Science |
|
dc.relation.ispartofseries |
PLoS ONE |
|
dc.rights |
info:eu-repo/semantics/restrictedAccess |
|
dc.rights.uri |
https://creativecommons.org/licenses/by-nc-nd/4.0/deed.es |
|
dc.subject |
Cerebrospinal fluid |
en_US |
dc.subject |
Tuberculosis |
en_US |
dc.subject |
Diagnostic medicine |
en_US |
dc.subject |
Tuberculosis diagnosis and management |
en_US |
dc.subject |
Mycobacterium tuberculosis |
en_US |
dc.subject |
Neuroimaging |
en_US |
dc.subject |
HIV |
en_US |
dc.subject |
Meningitis |
en_US |
dc.title |
Evaluation of the GeneXpert MTB/RIF in patients with presumptive tuberculous meningitis |
en_US |
dc.type |
info:eu-repo/semantics/article |
|
dc.identifier.doi |
https://doi.org/10.1371/journal.pone.0198695 |
|
dc.subject.ocde |
https://purl.org/pe-repo/ocde/ford#3.02.07 |
|
dc.subject.ocde |
https://purl.org/pe-repo/ocde/ford#3.01.02 |
|
dc.relation.issn |
1932-6203 |
|